Seguir
Gerburg Wulf
Gerburg Wulf
Associate Professor in Medicine, Harvard Medical School
Dirección de correo verificada de bidmc.harvard.edu
Título
Citado por
Citado por
Año
The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein
PJ Lu, G Wulf, XZ Zhou, P Davies, KP Lu
Nature 399 (6738), 784-788, 1999
9401999
Regulation of NF-κB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA
A Ryo, F Suizu, Y Yoshida, K Perrem, YC Liou, G Wulf, R Rottapel, ...
Molecular cell 12 (6), 1413-1426, 2003
8452003
Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c‐Jun towards cyclin D1
GM Wulf, A Ryo, GG Wulf, SW Lee, T Niu, V Petkova, KP Lu
The EMBO journal, 2001
6642001
Pin1 regulates turnover and subcellular localization of β-catenin by inhibiting its interaction with APC
A Ryo, M Nakamura, G Wulf, YC Liou, KP Lu
Nature cell biology 3 (9), 793-801, 2001
6132001
The prolyl isomerase Pin1 regulates amyloid precursor protein processing and amyloid-β production
L Pastorino, A Sun, PJ Lu, XZ Zhou, M Balastik, G Finn, G Wulf, J Lim, ...
Nature 440 (7083), 528-534, 2006
5882006
PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells
WJ Israelsen, TL Dayton, SM Davidson, BP Fiske, AM Hosios, G Bellinger, ...
Cell 155 (2), 397-409, 2013
5482013
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
C Pantelidou, O Sonzogni, M De Oliveria Taveira, AK Mehta, A Kothari, ...
Cancer discovery 9 (6), 722-737, 2019
5162019
The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response
H Zheng, H You, XZ Zhou, SA Murray, T Uchida, G Wulf, L Gu, X Tang, ...
Nature 419 (6909), 849-853, 2002
4922002
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer
A Juvekar, LN Burga, H Hu, EP Lunsford, YH Ibrahim, J Balmañà, ...
Cancer discovery 2 (11), 1048-1063, 2012
4592012
Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton
H Hu, A Juvekar, CA Lyssiotis, EC Lien, JG Albeck, D Oh, G Varma, ...
Cell 164 (3), 433-446, 2016
3602016
PIN1 is an E2F target gene essential for Neu/Ras-induced transformation of mammary epithelial cells
A Ryo, YC Liou, G Wulf, M Nakamura, SW Lee, KP Lu
Molecular and cellular biology, 2002
3472002
Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer
S Vinayak, SM Tolaney, L Schwartzberg, M Mita, G McCann, AR Tan, ...
JAMA oncology 5 (8), 1132-1140, 2019
3392019
TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes
NM Tung, ME Robson, S Ventz, CA Santa-Maria, R Nanda, PK Marcom, ...
Journal of Clinical Oncology 38 (36), 4274-4282, 2020
3362020
The prolyl isomerase Pin1 is a novel prognostic marker in human prostate cancer
G Ayala, D Wang, G Wulf, A Frolov, R Li, J Sowadski, TM Wheeler, KP Lu, ...
Cancer research 63 (19), 6244-6251, 2003
3362003
Phosphorylation-specific prolyl isomerization: is there an underlying theme?
G Wulf, G Finn, F Suizu, KP Lu
Nature cell biology 7 (5), 435-441, 2005
2972005
Role of Pin1 in the regulation of p53 stability and p21 transactivation, and cell cycle checkpoints in response to DNA damage
GM Wulf, YC Liou, A Ryo, SW Lee, KP Lu
Journal of Biological Chemistry 277 (50), 47976-47979, 2002
2952002
Prolyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer
A Ryo, YC Liou, KP Lu, G Wulf
Journal of cell science 116 (5), 773-783, 2003
2702003
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy
PK Morrow, GM Wulf, J Ensor, DJ Booser, JA Moore, PR Flores, Y Xiong, ...
Journal of Clinical Oncology 29 (23), 3126-3132, 2011
2612011
Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis
G Wulf, P Garg, YC Liou, D Iglehart, KP Lu
The EMBO journal 23 (16), 3397-3407, 2004
2242004
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial
PA Konstantinopoulos, WT Barry, M Birrer, SN Westin, KA Cadoo, ...
The Lancet Oncology 20 (4), 570-580, 2019
2222019
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20